Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTN - Palatin Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (50)	10/26/2001 2:07:54 PM
From: tuck	Respond to of 142

Rick, >>PRINCETON, N.J., Oct 26, 2001 (BW HealthWire) -- Preclinical studies have demonstrated that PT-141 significantly enhances sexual behavior in female rodents. Palatin Technologies, Inc. (AMEX: PTN chart, msgs) is developing PT-141 as an investigational treatment for male and female sexual dysfunction. Data from preclinical efficacy studies of PT-141 will be presented Saturday, October 27th, at the Female Sexual Function Forum (FSFF) Meeting in Boston, MA. The studies were performed by Palatin scientists in collaboration with Concordia University in Montreal. Annette M. Shadiack, Ph.D, Director, Biological Research at Palatin, will present the results. The studies' objectives were to evaluate PT-141's ability to enhance sexual behavior in female rodents. The studies were designed to allow for the evaluation of PT-141's effect on a variety of normal precopulatory sexual behaviors that are used by female rodents to heighten sexual arousal in their male partners. Female animals given PT-141 showed a significant, dose-responsive increase in a variety of these precopulatory sexual behaviors and actively solicited sexual contact from the males. Importantly, PT-141 treatment increased the female rodents' desire to copulate. "These data suggest that stimulation of melanocortin receptors in the brain by PT-141 selectively increased motivation for sexual activity in female rodents. The results indicate that PT-141 has potential to offer a unique treatment for women with desire disorders," said Dr. Shadiack. Perry Molinoff, M.D., Executive Vice President of Research & Development of Palatin said, "We are very excited about these results, which, in combination with the positive safety results from our Phase 1 clinical study in men, provide the basis for advancing this investigational drug into Phase 2 efficacy trials in women with Female Sexual Dysfunction (FSD) early next year." Palatin recently completed a Phase 1 safety trial with PT-141 in men that demonstrated a positive safety profile. PT-141 was well tolerated at all doses, there were no significant changes in blood pressure, heart rate or respiration rate, and investigators reported no serious side effects. A Phase 2A efficacy study of patients with erectile dysfunction is scheduled to begin later this year. PT-141 is a peptide analog of the neuropeptide hormone (alpha)-MSH ((alpha)-melanocyte-stimulating hormone). Scientists have determined that receptors for this class of molecules (melanocortin receptors) play a role in several behaviors including appetite and sexual arousal. Recent findings indicate the effects on sexual function may be stimulated through melanocortin receptors in the brain. As a result, Palatin believes PT-141 has the potential to offer a unique treatment for both male and female sexual dysfunction.<< snip First obvious customer for this compound would be Charles River Labs. Wouldn't even have to get FDA approval. ;~} Cheers, Tuck